CRISPR-Cas9 editing leads to widespread loss of the targeted chromosome in human T cells, but scientists recently discovered a way to prevent such loss.
Editing epitopes expressed on the surfaces of transplanted hematopoietic stem cells renders them resistant to AML treatments without affecting their critical functions.